Vertex Pharmaceuticals Inc (MIL:1VRTX)
€ 436.75 0 (0%) Market Cap: 114.49 Bil Enterprise Value: 109.92 Bil PE Ratio: 0 PB Ratio: 7.74 GF Score: 72/100

CRISPR Therapeutics AG and Vertex Pharmaceuticals Inc to Host AG Phase 1/2 CTX001™ Investor Update Transcript

Dec 09, 2020 / 01:00PM GMT
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the CTX001 Investor Event, sponsored by Vertex and CRISPR Therapeutics. (Operator Instructions) Please be advised that today's conference maybe recorded.

I would now like to hand the conference over to your speaker today, Mr. Michael Partridge, Senior Vice President of Investor Relations. Please go ahead, sir.

Michael Partridge
Vertex Pharmaceuticals Incorporated - SVP of IR

Good morning. This is Michael Partridge of Vertex. Susan Kim, Vice President of Investor Relations for CRISPR Therapeutics, and I are pleased to introduce today's call which will focus on the groundbreaking clinical data for our investigational gene-editing treatment, CTX001, in the treatment of sickle cell disease and beta thalassemia.

Providing prepared remarks on the call today are Dr. Reshma Kewalramani, Vertex's CEO and President; Dr. Haydar Frangoul, Medical Director of Pediatric Hematology and Oncology at Sarah Cannon Research Institute; and Dr. Sam Kulkarni, Chief Executive Officer of CRISPR

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot